80 patients undergoing transforaminal lumbar interbody fusion (TLIF) for degenerative lumbar disease were randomized to receive either lozoprofen (n=40) or a placebo (n=40). The primary outcome of interest included pain on a Visual Analog Scale (VAS) for up to 72 hours and sufentanil consumption for up to 48 hours. The secondary outcomes of interest included time to first analgesic request, incidence of adverse events, operative time, drainage volume, length of stay, Oswestry Disability Index (ODI), and the incidence of flurbiprofen axetil use. VAS pain scores were significantly lower in the lozoprofen group at 8, 16, 24, 36, 48, and 72 hours. Similarly, the time to first analgesic use was significantly longer in the lozoprofen group compared to placebo with significantly lower consumption of sufentanil and the incidence of adverse events. All other outcomes were similar between the two groups.